Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma.
Papakonstantinou D, Wang H, Bani MA, Mulder K, Dunsmore G, Boilève A, Jules-Clément G, Panunzi L, de Sousa LR, de la Calle Fabregat C, Deloger M, Signolle N, Gessain G, Nikolaev SI, Ducreux M, Hollebecque A, Ginhoux F, Blériot C.
Papakonstantinou D, et al. Among authors: de sousa lr.
Cancer Treat Res Commun. 2025;43:100939. doi: 10.1016/j.ctarc.2025.100939. Epub 2025 May 7.
Cancer Treat Res Commun. 2025.
PMID: 40354768
Free article.